The document attached hereto and the presentation of which it forms part (together the "Materials") have been prepared by Novacyt S.A. ("Novacyt" or the "Company"). The Materials are confidential and personal to you and are furnished to you by Novacyt's own personal and confidential information, in particular the information contained in the Company's SEC filings. By accessing, reading, distributing, or reproducing the Materials, you acknowledge and accept that such materials are intended to be used as confidential in nature and should be treated accordingly. The Materials do not constitute a prospectus or an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Corporation or any of its respective subsidiaries, and should not be construed as such. The Materials do not constitute a prospectus or an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Corporation or any of its respective subsidiaries, and should not be construed as such. The information and materials contained herein should be treated as confidential and may not be disclosed to any other person or entity.

Neither this presentation nor any copy of it, in whole or in part, or any of the Materials may be: (i) taken or transmitted into or out of the United States; (ii) distributed, directly or indirectly, in the United States of America or to any person (within the meaning of regulations made under the Securities Act, 1933, as amended; (iii) taken or transmitted into or out of Canada; (iv) distributed, directly or indirectly, in the Republic of Ireland or the United Kingdom or the South Africa or to any resident thereof; or (v) taken or transmitted into or distributed in Japan or to any resident thereof. Any failure to comply with these restrictions may constitute a violation of applicable securities laws and may subject you to civil or criminal penalties.

Neither this presentation nor any copy of it, in whole or in part, or any of the Materials may be: (i) taken or transmitted into or out of the United States; (ii) distributed, directly or indirectly, in the United States of America or to any person (within the meaning of regulations made under the Securities Act, 1933, as amended; (iii) taken or transmitted into or out of Canada; (iv) distributed, directly or indirectly, in the Republic of Ireland or the United Kingdom or the South Africa or to any resident thereof; or (v) taken or transmitted into or distributed in Japan or to any resident thereof. Any failure to comply with these restrictions may constitute a violation of applicable securities laws and may subject you to civil or criminal penalties.

The Materials are being made available on the basis that the recipients keep confidential any information contained therein, whether orally or in writing, in connection with the Company. The Materials are confidential and must not be copied, reproduced, published, distributed, disclosed or passed, directly or indirectly, to any other person or published, in whole or in part, for any purpose at any time without the prior written consent of the Company. By attending the presentation and/or accepting a copy of the Materials you agree to be bound by the foregoing provisions.

The information described in the Materials is confidential, price-sensitive and which has not been publicly disclosed. By your receipt of the Materials you recognise and accept that such information is being provided to you by the Company pursuant to Article 11 of MAR and you confirm, warrant and undertake that you will keep the information confidential and will not: (i) deal, or attempt to deal, in financial instruments (as defined in MAR) relating to that information, or encourage another person to deal or disclose the information before the inside information is made public; (ii) cancel or amend an order which has already been placed concerning a financial instrument to which such information relates; (iii) disclose the inside information to another person other than: in the course of the exercise of your employment, profession or duties; (iv) engage in behaviour which, on a reasonable basis, may amount to market abuse or market manipulation for the purposes of MAR. Recipients should take their own legal advice on the obligation to which they will be subject and the application of MAR and in particular make their own assessment of whether they are in possession of inside information and when such information ceases to be inside information.

Forward-looking Statements:
The Materials contain forward-looking statements. These statements relate to the future prospects, developments and business strategies of the Company and its subsidiaries (the "Group"). Forward-looking statements are identified by the use of such terms as "believe", "could", "estimate", "intend", "potential", "predict", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in the Materials are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group's actual results may vary materially from those expected, estimated or projected.
Our vision

Committed to becoming a leading, global clinical diagnostics company in infectious diseases

Our purpose

We protect lives from invisible threats by enabling informed clinical decision-making through quality diagnostics in the right place, at the right time
Presenters

Dave Allmond
Chief Executive Officer

- Appointed CEO of Novacyt in 2021
- Over 25 years of global experience in pharmaceuticals & biopharmaceutical companies
- Internationally experienced, strategic business leader with strong track record in global commercialisation
- Built & led multiple diverse, successful teams in dynamic growth companies including Amgen, Celgene & Amryt Pharma
- C-level executive with AIM and NASDAQ listed companies

James McCarthy
Chief Financial Officer

- Appointed CFO of Novacyt in 2021
- Over 30 years in international manufacturing and industrial businesses in both consumer and B2B
- CFO in both Private Equity and public businesses.
- FCCA qualified over 30 years with broad commercial, supply chain and M&A experience
2022 Unaudited Half Year Results
H1 2022 and post-period operational highlights

- Developed semi-automated, scalable workflow solution.
- Accelerated menu availability with access to >40 clinical ID assays.
- Launched an LFT digital reader for use in conjunction with 18 non COVID-19 assays
- Launched an RUO monkeypox PCR assay and an RUO assay for adenovirus F41
- Launch of defence and counterclaim against DHSC
- Completed closure of Microgen Bioproducts and Lab21 and fully delivered restructuring programme announced in July.
- Relaunched RUO portfolio in July with encouraging early contract wins.
- PROmate® COVID-19 1G, 2G and exsig™ COVID-19 Direct Real-Time PCR tests received CTDA approval
- Granted a key patent for ORF1a/b, which will lead to a corporation tax credit against future profits on related assays
### H1 2022 unaudited – Profit & Loss

**£'000**

<table>
<thead>
<tr>
<th></th>
<th>H1 2022</th>
<th>H1 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Continuing Operations</strong>*</td>
<td><strong>Consol</strong></td>
<td><strong>Consol</strong></td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td>16,508</td>
<td>52,201</td>
</tr>
<tr>
<td>**Gross profit **</td>
<td>4,010</td>
<td>1,177</td>
</tr>
<tr>
<td><strong>Gross profit %</strong></td>
<td>24%</td>
<td>2%</td>
</tr>
<tr>
<td><strong>OPEX</strong></td>
<td>(11,148)</td>
<td>(13,301)</td>
</tr>
<tr>
<td><strong>EBITDA</strong></td>
<td>(7,138)</td>
<td>(12,124)</td>
</tr>
<tr>
<td><strong>EBITDA %</strong></td>
<td>-43%</td>
<td>-23%</td>
</tr>
<tr>
<td>**Adjusted EBITDA **</td>
<td>(7,138)</td>
<td>23,646</td>
</tr>
<tr>
<td>**Recurring operating loss *****</td>
<td>(8,179)</td>
<td>(12,958)</td>
</tr>
<tr>
<td><strong>Operating loss</strong></td>
<td>(8,712)</td>
<td>(12,958)</td>
</tr>
<tr>
<td><strong>Other financial income and expenses</strong></td>
<td>1,628</td>
<td>(1,421)</td>
</tr>
<tr>
<td><strong>Income tax credit</strong></td>
<td>2,041</td>
<td>2,295</td>
</tr>
<tr>
<td><strong>Loss after tax from continuing operations</strong></td>
<td>(5,043)</td>
<td>(12,084)</td>
</tr>
<tr>
<td><strong>Loss from discontinued operations</strong></td>
<td>(3,656)</td>
<td>(591)</td>
</tr>
<tr>
<td><strong>Loss after tax attributable to the owners</strong></td>
<td>(8,699)</td>
<td>(12,675)</td>
</tr>
</tbody>
</table>

* Following the 28 April 2022 announcement where Novacyt announced its intention to close Microgen Bioproducts and Lab21 Healthcare the net results of the Lab21 Products segment for 2021 and 2022 has been reported on a separate line ‘Loss from discontinued operations’ in accordance with IFRS 5, “Non-current Assets Held for Sale and Discontinued Operations”.

** Due to the ongoing commercial dispute with the DHSC, £35.8m exceptional cost of sales were incurred in H1 2021 (H1 2022: £nil) that were one-off in nature. The two largest items were a £26.1m stock provision, as a result of the Group buying stock to fulfil expected future DHSC orders that did not materialise; and the expensing of £6.9m of stock delivered to the DHSC which has not been paid for as it is now part of the ongoing contract dispute.

*** H1 2022 recurring operating loss is stated before £0.5m of non-recurring charges in relation to the ongoing DHSC contract dispute.

- Group revenue of £16.5m in H1 2022 compared with £52.2m in H1 2021 predominantly driven by the expected decline in COVID-19 related sales.
- Group gross profit improved to £4.0m (24%) in H1 2022 (H1 2021: £1.2m (2%)). The latter was impacted by the one-off exceptional costs relating to the DHSC dispute.
- The H1 2022 gross profit was reduced as a result of stock provisions and write-offs relating to lower forecast COVID-19 sales. Excluding the impact of these items the Gross Margin would have been in excess of 60%.
- Group adjusted EBITDA loss of £7.1m in H1 2022 before exceptional (H1 2021: £23.6m profit).
- The discontinued operations losses widen to £3.7m in H1 2022 from £0.6m in H1 2021.
- Loss after tax has decreased to £8.7m in H1 2022 from £12.7m in H1 2021.
H1 2022 unaudited balance sheet and cash

- Cash position at 30 June 2022 was £99.6m, compared with £101.7m at 31 December 2021, and the Company remains debt free.
- WCAP (excluding cash) has fallen by one third from £18.2 at year end to £11.9m at the end of June based on the falling revenues and actions taken in relation to COVID-19 stock.
- Capital expenditure in H1 2022 fell to £0.3m compared to £2.0m in H1 2021, after the Company heavily invested in insourcing manufacturing during 2021.
- Granted the key patent (ORF1a/b), with patent number GB2593010. This means that the effective rate of tax on profits (adjusted for certain rules) derived from the sale of products incorporating this patent is close to 10% rather than the current UK corporation tax rate of 19%.

### Balance Sheet

<table>
<thead>
<tr>
<th></th>
<th>Jun-22</th>
<th>Dec-21</th>
<th>Jun-22</th>
<th>Dec-21</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Goodwill</td>
<td>11,638</td>
<td>11,471</td>
<td>54,632</td>
<td>54,646</td>
</tr>
<tr>
<td>Right-of-use assets</td>
<td>552</td>
<td>1,788</td>
<td>78,035</td>
<td>87,169</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>3,439</td>
<td>4,594</td>
<td>132,667</td>
<td>141,815</td>
</tr>
<tr>
<td>Deferred tax assets</td>
<td>4,796</td>
<td>3,143</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other non-current assets</td>
<td>3,625</td>
<td>3,918</td>
<td>1,245</td>
<td>1,224</td>
</tr>
<tr>
<td>Total non-current assets</td>
<td>24,050</td>
<td>24,914</td>
<td>1,324</td>
<td>1,446</td>
</tr>
<tr>
<td>Inventories</td>
<td>4,255</td>
<td>11,461</td>
<td>425</td>
<td>308</td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>35,293</td>
<td>38,499</td>
<td>2,994</td>
<td>2,978</td>
</tr>
<tr>
<td>Tax receivables</td>
<td>1,000</td>
<td>5,034</td>
<td>347</td>
<td>424</td>
</tr>
<tr>
<td>Other current assets</td>
<td>1,889</td>
<td>2,043</td>
<td>8,128</td>
<td>17,190</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>99,641</td>
<td>101,746</td>
<td>21,992</td>
<td>21,290</td>
</tr>
<tr>
<td>Total current assets</td>
<td>142,078</td>
<td>158,783</td>
<td>30,467</td>
<td>38,904</td>
</tr>
<tr>
<td>TOTAL ASSETS</td>
<td>166,128</td>
<td>183,697</td>
<td>166,128</td>
<td>183,697</td>
</tr>
</tbody>
</table>

---

**N O V A C Y T**

8
Delivery against strategy
Corporate strategy – two key imperatives

Prior to the COVID-19 pandemic, Novacyt was a £10-15m life sciences/RUO business

Global first responder

Build the base

Innovation engine

Future outbreak

Human IVD

Instruments

Life sciences/RUO

Revenue

Time

COVID-19

Future outbreak

Future outbreak

Illustrative
Evolving beyond the pandemic to a sustainable growth business, serving high unmet needs in infectious diseases

Drivers of transition

- **Portfolio development**
  - Relaunch RUO portfolio in Q2 2022, launch e-commerce platform, deliver clinical IVD portfolio

- **Instrumentation**
  - Integrated with life sciences/RUO and IVD portfolios

- **Geographic expansion**
  - Increasing presence, leveraging adjacent markets and building distributor network

- **Business development**
  - Innovation for disruptive technologies
  - Accelerating molecular portfolio
  - Strategic transactions

2021

~2026

Transition

- 80% COVID-19 revenues
- 20% non-COVID-19 revenues
- < 10% COVID-19 revenues
- > 90% non-COVID-19 revenues

2021-2026

Drivers of transition

- Portfolio development
  - Relaunch RUO portfolio in Q2 2022, launch e-commerce platform, deliver clinical IVD portfolio

- Instrumentation
  - Integrated with life sciences/RUO and IVD portfolios

- Geographic expansion
  - Increasing presence, leveraging adjacent markets and building distributor network

- Business development
  - Innovation for disruptive technologies
  - Accelerating molecular portfolio
  - Strategic transactions

Evolving beyond the pandemic to a sustainable growth business, serving high unmet needs in infectious diseases
### Significant progress in building the base business (1)

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Actions</th>
<th>Outcomes</th>
</tr>
</thead>
</table>
| **Portfolio development** | • Signed a global distribution agreement with Clonit srl with access to over 40 CE marked clinical assays  
• Launched E-commerce platform in Q2 2022  
• Relaunched RUO portfolio in July 2022  
• Progressing organic R&D for mid-term menu expansion. | • Broad, approved, clinical menu and enhanced workflow available now in STI and in Q1 2023 in respiratory and GI  
• Launch in Europe, our initial target geography, (CE marked) where we estimate a market size of circa £470m growing at 10% pa  
• Early RUO wins in Q3 with Salmon testing in Canada and Salmonella testing in Poland  
• Advanced design of 2 PCR panels for near-patient testing in gastro-intestinal viruses and bacteria infections |
| **Instrumentation** | • Sourced extraction system to integrate with clinical workflow  
• Enhancing Co-prep automation with flexibility for PROmate®, genesig® and dry assays  
• Launched a new lateral flow test (LFT) reader for use in conjunction with 18 non COVID-19 Pathflow® assays for patient screening in STI, GI, respiratory and insect-borne infections | • Launching decentralised workflow for use in spoke laboratories to enable deployment of expanded clinical (IVD) menu  
• Now participating in significant lateral flow tenders across EU |
Significant progress in building the base business (2)

Strategy

Geographic expansion
Increasing presence, leveraging adjacent markets and building distributor network

Business development
Innovation for disruptive technologies
Accelerating molecular portfolio
Strategic transactions

Actions

• Deployed talent in key geographies
• Optimising global distributor network to build coverage in new markets, ensure optimal RUO and clinical portfolio coverage across priority markets
• Agreements for extraction, sample handling digital reader and broad clinical assay menu already completed
• Further work on portfolio development in progress across target disease areas to accelerate approved menu to commercialise
• Significantly enhanced BD funnel and deal flow for M&A

Outcomes

• Reduced active distributor network by over 75% to focus on key partners
• Added coverage in 18 new countries across EMEA. Optimising distributor network in US, APAC and LATAM
• Commenced distributor training on full portfolio including expanded clinical portfolio and workflow
• Accelerated launch of clinical ID menu by ~2 years and developing integrated workflow to be completed by Q2 2023
• Identified potential mini-GI panels approved under IVDD for validation and potential distribution
• Strategically aligned/executable opportunities coming through the funnel
**Promoting comprehensive product portfolio to drive near term growth**

<table>
<thead>
<tr>
<th>PROmate®</th>
<th>PathFlow®</th>
<th>MyGo, Q Series CO-prep™ &amp; VersaLab™</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simple, convenient direct to PCR for near patient workflow. Investing in R&amp;D on this platform.</td>
<td>Extensive lateral flow portfolio and digital reader for clinical diagnostics/screening</td>
<td>qPCR instruments, liquid handling, extraction and mobile laboratory taking testing to the front line</td>
</tr>
<tr>
<td>genesig®</td>
<td>SNPsig®</td>
<td></td>
</tr>
<tr>
<td>Broad clinical &amp; research use PCR portfolio for pathogen detection in veterinary, human, food, and environment settings</td>
<td>For the rapid detection, identification and monitoring of SARS-CoV-2 variants of concern</td>
<td></td>
</tr>
</tbody>
</table>
Relaunching world class, broad range of research use only/life sciences assays and instrumentation

- Veterinary
- Food
- Environment
- Human

MyGo range of 16 and 32 well, open platform qPCR instruments offer an ideal solution for research customers
Investing in organic R&D and business development to expand our clinical portfolio in 4 key therapeutic areas

- COVID-19
- Respiratory infections
- Gastrointestinal infections
- Sexually transmitted infections
- Insect-borne viruses
- ...and beyond

~2 years under IVDR

NOVACYT
Enhancing scalable, semi-automated workflow taking clinical testing to the front line

Sample collection

Co-Prep™ extraction and automated liquid handling assay set-up
Convenience with walkaway time
Reduced contamination & human error risk

"Q Series" PCR, 16 & 32 well Instruments
Rapid results
High sensitivity & specificity. Up to 1000 tests per day

Combined with a VersaLab to provide ultimate flexibility
Launching a broad menu of approved assays across respiratory, STI, GI and insect borne infections

**Phase 1**
Chemistry supply only

**Phase 2**
q16/32 instrument supported

**Phase 3**
Full workflow supported (CO-Prep extraction, automation and PCR instrument validation)

- **STI**
- **Respiratory**
- **GI**
- **Transplant**
- **Insect-borne**

- September 2022
- Q1 2023
- Q2 2023

*To be determined in parallel with regulatory strategy*
Continuing to be a global first responder in infectious diseases

Strong track record of being a "first responder" to disease outbreaks.
Rapid response to Monkeypox and Adenovirus F41 in 2022

- 2006: Inception of Lab 21 followed by Novacyt S.A in 2006
- 2009: First Response
  - First available assay for H1N1 Swine Flu
- 2012: Listing onto Alternext Stock Exchange in France
- 2014: Acquisition of Lab21 business
- 2015: First Response
  - Rapid response to 2014 Ebola epidemic in West Africa with CE-IVD PCR test
- 2016: Acquisition of Primerdesign
- 2017: Listing AIM LSE
  - Admission onto London Stock Exchange, dual listing with France
- 2017: First Response
  - Launch of the first CE-IVD approved molecular product for Zika disease
- 2020: Acquisition of IT-IS
- 2021: First Response
  - Launch of 15 new assays to support COVID-19
- 2022: First Response
  - Launch of RUO assays for Monkeypox & Adenovirus F41
Three key areas of focus

1. Innovation
   - Innovation to in-license & develop disruptive clinical diagnostic technologies and workflow
     - Point of care Biosensor in development ✓

2. Acceleration
   - Accelerating the molecular portfolio (AMP)
     - Molecular assay menu expansion ✓
     - LFT digital reader ✓
     - Expanding liquid handler to broader chemistry for automation ✓
     - Extraction capability by Q4

3. Strategy
   - Strategic transactions/M&A to diversify and build for scale
     - Built significant funnel to deliver strategically aligned, transactable deals ✓

Delivering on inorganic growth Objectives through business development

We plan to deploy capital in strategic transactions to accelerate growth
Launch of new clinical IVD workflow, in partnership with Clonit, with access to a broad menu

Launched LFT digital reader for use in conjunction with extensive LFT menu

Re-launch of RUO portfolio and refreshing route to market with more focussed and streamlined distributors and pilot launch of e-commerce

Right-sizing cost base in line with falling COVID-19 sales, fully delivered on announced restructuring

Redoubling business development activities to find the right investment options for cash resources

M&A funnel delivering opportunities for strategic transactions

Predicted Q3 2022 revenue of circa £2.0m, with similar levels expected in Q4 2022, resulting in an anticipated EBITDA loss for the full year of circa £13.5m

The Board believes that Novacyt remains well positioned to leverage its core capabilities to become a leading, global clinical diagnostics company